Search

Your search keyword '"Sriuranpong, V."' showing total 11 results
Start Over Author "Sriuranpong, V." Language undetermined
11 results on '"Sriuranpong, V."'

1. Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Author

Clingan, P., Rietschel, P., Gladkov, O., Sriuranpong, V., Gullo, G., Lowy, I., Seebach, F., Lee, S., Pouliot, J., Mcginniss, J., Rizvi, N., Bondarenko, I., Sezer, A., Kilickap, S., GÜMÜŞ, MAHMUT, ÖZGÜROĞLU, Mustafa, Gogishvili, M., Turk, H. M., Cicin, I., and Bentsion, D.

Subjects
Subgroup Analysis from EMPOWER-Lung 1-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021 [Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC]
Published
2021

2. Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Author

Kilickap, S., Sezer, A., Gumus, M., Bondarenko, I., Ozguroglu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Li, S., Lee, S., Makharadze, T., Paydas, S., Nechaeva, M., Seebach, F., Weinreich, D. M., Yancopoulos, G. D., Gullo, G., Lowy, I., Rietschel, P., and TÜRK, HACI MEHMET

Subjects
Kilickap S., Sezer A., Gumus M., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.3, 2021
Published
2021

3. EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

Author

Sezer, A., Kilickap, S., Gumus, M., Bondarenko, I., ÖZGÜROĞLU, Mustafa, Gogishvili, M., TÜRK, HACI MEHMET, Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Li, S., Lee, S., Gullo, G., Lowy, I., Rietschel, P., and TÜRK, HACI MEHMET

Subjects
=+50%25-%2C+ESMO+Virtual+Congress%2C+ELECTR+NETWORK%2C+19+Eylül+-+18+Ekim+2020%2C+cilt%2E31+[Sezer+A%2E%2C+Kilickap+S%2E%2C+Gumus+M%2E%2C+Bondarenko+I%2E%2C+ÖZGÜROĞLU+M%2E%2C+Gogishvili+M%2E%2C+TÜRK+H%2E+M%2E+%2C+Cicin+I%2E%2C+Bentsion+D%2E%2C+Gladkov+O%2E%2C+et+al%2E%2C+-EMPOWER-Lung+1]%22">Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%-, ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31 [Sezer A., Kilickap S., Gumus M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., TÜRK H. M. , Cicin I., Bentsion D., Gladkov O., et al., -EMPOWER-Lung 1]
Published
2020

4. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Author

Yao, James C, Fazio, Nicola, Singh, Simron, Buzzoni, Roberto, Carnaghi, Carlo, Wolin, Edward, Tomasek, Jiri, Raderer, Markus, Lahner, Harald, Voi, Maurizio, Pacaud, Lida Bubuteishvili, Rouyrre, Nicolas, Sachs, Carolin, Valle, Juan W, Delle Fave, Gianfranco, Van Cutsem, Eric, Tesselaar, Margot, Shimada, Yasuhiro, Oh, Do-Youn, Strosberg, Jonathan, Kulke, Matthew H, Pavel, Marianne E, Raderer, M, Pall, G, Van Cutsem, E, Borbath, I, Geboes, K, Peeters, M, Asmis, T, Kocha, W, Rayson, D, Ruether, J, Singh, S, Sideris, L, Kennecke, H, Wang, J, Shen, L, Xu, J, Qian, J, Jia, L, Maya, L F, Melichar, B, Sedlackova, E, Tomasek, J, Pavel, M, Bojunga, J, Malfertheiner, P, Vogel, A, Weber, M, Hörsch, D, Kaltsas, G, Papai, Z, Toth, M, Carnaghi, C, Luppi, G, Fazio, N, Tomassetti, P, Delle Fave, G, Cartenì, G, Buzzoni, R, Barone, C, Berruti, A, Giuffrida, D, Tortora, G, Di Costanzo, F, Tafuto, S, Ito, T, Okita, N, Komoto, I, Kattan, J, Shamseddine, A, Tesselaar, M, Jarzab, B, Ruchala, M, Vladimirova, L, Raef, H, Salek, T, Ruff, P, Kim, T W, Park, Y S, Oh, D-Y, Lee, M-A, Choi, H J, Capdevila, J, Salazar, R, Zoilo, J J R, Chen, J-S, Wu, C-C, Chen, Y-Y, Chao, Y, Yeh, K-H, Sriuranpong, V, Thongprasert, S, Turna, H, Sevinc, A, Valle, J, Sarker, D, Reed, N, Cave, J, Frilling, A, Corrie, P, Fanta, P, Yao, J, Strosberg, J, Verma, U, Libutti, S, Natale, R, Pommier, R, Lubner, S, Starodub, A, Kulke, M, Sigal, D, Polite, B, Lieu, C, Hande, K, Reidy-Lagunes, D, McCollum, A, and Forero, L

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Lung Neoplasms, Medizin, Antineoplastic Agents, Neuroendocrine tumors, Placebo, Gastroenterology, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Clinical endpoint, Humans, Everolimus, Aged, Gastrointestinal Neoplasms, Aged, 80 and over, Performance status, business.industry, Sunitinib, Medicine (all), Hazard ratio, General Medicine, Middle Aged, medicine.disease, Survival Analysis, 3. Good health, Surgery, Neuroendocrine Tumors, 030104 developmental biology, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Female, business, medicine.drug
Abstract

Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population.In the randomised, double-blind, placebo-controlled, phase 3 RADIANT-4 trial, adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled from 97 centres in 25 countries worldwide. Eligible patients were randomly assigned in a 2:1 ratio by an interactive voice response system to receive everolimus 10 mg per day orally or identical placebo, both with supportive care. Patients were stratified by tumour origin, performance status, and previous somatostatin analogue treatment. Patients, investigators, and the study sponsor were masked to treatment assignment. The primary endpoint was progression-free survival assessed by central radiology review, analysed by intention to treat. Overall survival was a key secondary endpoint. This trial is registered with ClinicalTrials.gov, number NCT01524783.Between April 3, 2012, and Aug 23, 2013, a total of 302 patients were enrolled, of whom 205 were allocated to everolimus 10 mg per day and 97 to placebo. Median progression-free survival was 11·0 months (95% CI 9·2-13·3) in the everolimus group and 3·9 months (3·6-7·4) in the placebo group. Everolimus was associated with a 52% reduction in the estimated risk of progression or death (hazard ratio [HR] 0·48 [95% CI 0·35-0·67], p0·00001). Although not statistically significant, the results of the first pre-planned interim overall survival analysis indicated that everolimus might be associated with a reduction in the risk of death (HR 0·64 [95% CI 0·40-1·05], one-sided p=0·037, whereas the boundary for statistical significance was 0·0002). Grade 3 or 4 drug-related adverse events were infrequent and included stomatitis (in 18 [9%] of 202 patients in the everolimus group vs 0 of 98 in the placebo group), diarrhoea (15 [7%] vs 2 [2%]), infections (14 [7%] vs 0), anaemia (8 [4%] vs 1 [1%]), fatigue (7 [3%] vs 1 [1%]), and hyperglycaemia (7 [3%] vs 0).Treatment with everolimus was associated with significant improvement in progression-free survival in patients with progressive lung or gastrointestinal neuroendocrine tumours. The safety findings were consistent with the known side-effect profile of everolimus. Everolimus is the first targeted agent to show robust anti-tumour activity with acceptable tolerability across a broad range of neuroendocrine tumours, including those arising from the pancreas, lung, and gastrointestinal tract.Novartis Pharmaceuticals Corporation.

Published
2015

10. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Author

Rafael Rosell, Alice T. Shaw, Ali Zeaiter, Shirish M. Gadgeel, Emmanuel Mitry, Bogdana Balas, Jin S. Ahn, Maurice Perol, Johannes Noe, Sai-Hong Ignatius Ou, Peter N. Morcos, D. Ross Camidge, Solange Peters, Tony Mok, Dong Wan Kim, Rafal Dziadziuszko, Sophie Golding, ALEX Trial Investigators, Nordman, I., Pittman, K., Dear, R., Lwin, Z., Briggs, P., Pavlakis, N., Ceric, T., Mehic, B., Stanetic, M., Franke, F.A., Castro, G., Santo Borges, G., Pereira, J., Brust, L., Santos, L., Cruz, M., Ribeiro, R., De Azevedo, S., Neron, Y.V., Sangha, R., Cohen, V., Burkes, R., Abdelsalam, M., Yadav, S., Cheema, P., Yanez, E., Aren, O., Zhou, C., Zhang, L., Liu, X., Corrales Rodriguez, L., Meldgaard, P., Soerensen, J.B., McCulloch, T., Rodriguez, N., Gaafar, R., Abdel Azeem, H., Coudert, B., Moro-Sibilot, D., Lena, H., Bennouna, J., Cortot, A., Veillon, R., Cadranel, J., Barlesi, F., Reck, M., Mezger, J., von Pawel, J., Fischer, J.R., Dickgreber, N.K., Zarogoulidis, K., Syrigos, K., Georgoulias, V., Agelaki, S., Castro-Salguero, H., Ho, J., Chan, S.H., Cheng, C.K., Ng, A., Stemmer, S., Wollner, M., Gottfried, M., Dudnik, J., Cyjon, A., Heching, N., Novello, S., Tiseo, M., Platania, M., Misino, A., Gridelli, C., Ciardiello, F., Favaretto, A., De Marinis, F., Longo, F., Bordonaro, R., Dazzi, C., Chiari, R., Mercuri, E., Macedo, E., Rodriguez Cid, J.R., McKeage, M., Vera, L., Morón Escobar, H.D., Rodriguez, M., Mas, L., Ramlau, R., Kowalski, D., Szczesna, A., Kazarnowicz, A., Milanowski, J., Luboch-Kowal, J., Oliveira, J., Barata, F., Almodovar, T., Lee, J.S., Cho, B.C., Kim, S.W., Han, J.Y., Karaseva, N., Stroyakovskii, D., Kuzmin, A., Smolin, A., Laktionov, K., Ragulin, Y., Filippov, A., Levchenko, E., Jovanovic, D., Perin, B., Andric, Z., Soo, R., Tan, E.H., De Castro Carpeno, J., Provencio Pulla, M., Garrido Lopez, P., Felip Font, E., Morano Bueno, T., Sanchez, A., Isla Casado, D., Ponce Aix, S., Reguart Aransay, N., Viteri Ramirez, S., Rodriguez Abreu, D., Sanchez Torres, J.M., Massuti Sureda, B., Ramos Vazquez, M., Tabernero, J.M., Curioni, A., Rothschild, S., Scherz, A., Chiu, C.H., Su, W.C., Yang, CHJ, Chang, G.C., Hsia, T.C., Yang, C.T., Tharavichitkul, E., Pongthai, P., Arpornwirat, W., Geater, S., Srimuninnimit, V., Sriuranpong, V., Demirkazik, A., Goker, E., Harputluoglu, H., Cicin, I., Kose, F., Erman, M., Bondarenko, I., Vinnyk, Y., Shparyk, Y., Golovko, Y., Lal, R., Forster, M., Califano, R., Skailes, G., Thompson, J., Mekhail, T., Polikoff, J., Spigel, D., Waqar, S., Hermann, R., Deo, E., Simon, G., Rybkin, I., Kaywin, P.R., Uyeki, J., Gubens, M., Limaye, S., Gerber, D.E., Leal, T., Spira, A.I., Bazhenova, L., Cetnar, J., Socinski, M., Jahanzeb, M., Kabbinavar, F., Lawler, W.E., Hancock, M.R., Raez, L.E., DiCarlo, B.A., Lowe, T.E., Fidler, M., Ross, H., Davidson, S.J., Sanchez, J.D., Hamm, J., Kerr, S., Belman, N., Baker, S., Naraev, B., Jung, G., Edelman, M., Feldman, L., Belani, C., and Pakkala, S.

Subjects
Adult, Male, 0301 basic medicine, Oncology, Alectinib, medicine.medical_specialty, Pathology, Lung Neoplasms, Brigatinib, Pyridines, medicine.drug_class, Carbazoles, Antineoplastic Agents, Kaplan-Meier Estimate, Aged, 80 and over, Animals, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Carbazoles/adverse effects, Carbazoles/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/mortality, Central Nervous System Neoplasms/drug therapy, Central Nervous System Neoplasms/secondary, Disease-Free Survival, Female, Follow-Up Studies, Humans, Intention to Treat Analysis, Lung Neoplasms/drug therapy, Lung Neoplasms/mortality, Middle Aged, Piperidines/adverse effects, Piperidines/therapeutic use, Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/therapeutic use, Pyrazoles/adverse effects, Pyrazoles/therapeutic use, Pyridines/adverse effects, Pyridines/therapeutic use, Receptor Protein-Tyrosine Kinases/analysis, Receptor Protein-Tyrosine Kinases/antagonists & inhibitors, Young Adult, Central Nervous System Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Piperidines, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Internal medicine, medicine, Anaplastic lymphoma kinase, Lung cancer, Protein Kinase Inhibitors, Crizotinib, Ceritinib, business.industry, Receptor Protein-Tyrosine Kinases, General Medicine, medicine.disease, Lorlatinib, ALK inhibitor, 030104 developmental biology, 030220 oncology & carcinogenesis, Pyrazoles, business, medicine.drug
Abstract

Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P

Published
2017

11. Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus

Author

Maximino Bello, Joong B. Ahn, Hwai L. Kong, Su Z. Zhang, Michael Shaw, Fortunato Ciardiello, Jin Li, Virote Sriuranpong, Li-Tzong Chen, Ka O. Lam, Ann-Lii Cheng, Aru W Sudoyo, Young Suk Park, Jaw-Yuan Wang, Gwo F. Ho, Brigette B.Y. Ma, Ashok K. Vaid, Clause Henning Köhne, Jun Zhang, Tian S. Liu, Catherine Teh, Tae Won Kim, Chaiyut Charoentum, Gilberto Lopes, Cheng, Al, Li, J, Vaid, Ak, Ma, Bb, Teh, C, Ahn, Jb, Bello, M, Charoentum, C, Chen, Lt, de Lima Lopes G., Jr, Ho, Gf, Kong, Hl, Lam, Ko, Liu, T, Park, Y, Sriuranpong, V, Sudoyo, Aw, Wang, Jy, Zhang, J, Zhang, Sz, Ciardiello, Fortunato, Köhne, Ch, Shaw, M, and Kim, Tw

Subjects
Oncology, Lung Neoplasms, Organoplatinum Compounds, Oxaloacetates, Colorectal cancer, Leucovorin, Cetuximab, medicine.disease_cause, Deoxycytidine, FOLFOX, Antineoplastic Combined Chemotherapy Protocols, Panitumumab, Liver Neoplasms, Gastroenterology, Antibodies, Monoclonal, Combined Modality Therapy, Magnetic Resonance Imaging, Bevacizumab, ErbB Receptors, Drug Combinations, Colonic Neoplasms, Practice Guidelines as Topic, KRAS, Fluorouracil, Guideline Adherence, medicine.drug, medicine.medical_specialty, Asia, Antibodies, Monoclonal, Humanized, Capecitabine, Proto-Oncogene Proteins p21(ras), Internal medicine, Proto-Oncogene Proteins, medicine, Humans, Neoplasm Staging, Tegafur, business.industry, Rectal Neoplasms, Metastasectomy, medicine.disease, digestive system diseases, Surgery, Oxaliplatin, Oxonic Acid, ras Proteins, Camptothecin, business, Tomography, X-Ray Computed
Abstract

Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional 'real-world' experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results